CCK2 receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours

Meike Körner, Beatrice Waser, Jean Claude Reubi, Laurence J Miller

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The wild-type cholecystokinin type 2 (CCK2) receptor is expressed in many gastrointestinal and lung tumours. A splice variant of the CCK2 receptor with retention of intron 4 (CCK2Ri4sv) showing constitutive activity associated with increased tumour growth was described in few colorectal, pancreatic and gastric cancers. Given the potential functional and clinical importance of this spliceoform, its occurrence was quantitatively characterized in a broad collection of 81 gastrointestinal and lung tumours, including insulinomas, ileal carcinoids, gastrointestinal stromal tumours (GIST), gastric, colorectal and pancreatic ductal adenocarcinomas, cholangiocellular and hepatocellular carcinomas, small cell lung cancers (SCLC), non-SCLC (nSCLC) and bronchopulmonary carcinoids, as well as 21 samples of corresponding normal tissues. These samples were assessed for transcript expression of total CCK2 receptor, wild-type CCK2 receptor and CCK2Ri4sv with end-point and real-time RT-PCR, and for total CCK2 receptor protein expression on the basis of receptor binding with in vitro receptor autoradiography. Wild-type CCK2 receptor transcripts were found in the vast majority of tumours and normal tissues. CCK2Ri4sv mRNA expression was present predominantly in insulinomas (incidence 100%), GIST (100%) and SCLC (67%), but rarely in pancreatic, colorectal and gastric carcinomas and nSCLC. It was not found in wild-type CCK2 receptor negative tumours or any normal tissues tested. CCK2Ri4sv transcript levels in individual tumours were low, ranging from 0.02% to 0.14% of total CCK2 receptor transcripts. In conclusion, the CCK2Ri4sv is a marker of specific gastrointestinal and lung tumours. With its high selectivity for and high incidence in SCLC and GIST, it may represent an attractive clinical target.

Original languageEnglish (US)
Pages (from-to)933-943
Number of pages11
JournalJournal of Cellular and Molecular Medicine
Volume14
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Cholecystokinin B Receptor
Introns
Lung
Gastrointestinal Stromal Tumors
Neoplasms
Small Cell Lung Carcinoma
Insulinoma
Carcinoid Tumor
Colorectal Neoplasms
Stomach
Pancreatic Ductal Carcinoma
Cholangiocarcinoma
Incidence
Autoradiography
Pancreatic Neoplasms
Non-Small Cell Lung Carcinoma
Stomach Neoplasms
Real-Time Polymerase Chain Reaction
Hepatocellular Carcinoma
Adenocarcinoma

Keywords

  • CCK receptor intron 4 splice variant
  • Gastrointestinal stromal tumour
  • Receptor autoradiography
  • RT-PCR
  • Small cell lung cancer

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine

Cite this

CCK2 receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours. / Körner, Meike; Waser, Beatrice; Reubi, Jean Claude; Miller, Laurence J.

In: Journal of Cellular and Molecular Medicine, Vol. 14, No. 4, 04.2010, p. 933-943.

Research output: Contribution to journalArticle

@article{a6707991190241918ee6fdd6fe63aef1,
title = "CCK2 receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours",
abstract = "The wild-type cholecystokinin type 2 (CCK2) receptor is expressed in many gastrointestinal and lung tumours. A splice variant of the CCK2 receptor with retention of intron 4 (CCK2Ri4sv) showing constitutive activity associated with increased tumour growth was described in few colorectal, pancreatic and gastric cancers. Given the potential functional and clinical importance of this spliceoform, its occurrence was quantitatively characterized in a broad collection of 81 gastrointestinal and lung tumours, including insulinomas, ileal carcinoids, gastrointestinal stromal tumours (GIST), gastric, colorectal and pancreatic ductal adenocarcinomas, cholangiocellular and hepatocellular carcinomas, small cell lung cancers (SCLC), non-SCLC (nSCLC) and bronchopulmonary carcinoids, as well as 21 samples of corresponding normal tissues. These samples were assessed for transcript expression of total CCK2 receptor, wild-type CCK2 receptor and CCK2Ri4sv with end-point and real-time RT-PCR, and for total CCK2 receptor protein expression on the basis of receptor binding with in vitro receptor autoradiography. Wild-type CCK2 receptor transcripts were found in the vast majority of tumours and normal tissues. CCK2Ri4sv mRNA expression was present predominantly in insulinomas (incidence 100{\%}), GIST (100{\%}) and SCLC (67{\%}), but rarely in pancreatic, colorectal and gastric carcinomas and nSCLC. It was not found in wild-type CCK2 receptor negative tumours or any normal tissues tested. CCK2Ri4sv transcript levels in individual tumours were low, ranging from 0.02{\%} to 0.14{\%} of total CCK2 receptor transcripts. In conclusion, the CCK2Ri4sv is a marker of specific gastrointestinal and lung tumours. With its high selectivity for and high incidence in SCLC and GIST, it may represent an attractive clinical target.",
keywords = "CCK receptor intron 4 splice variant, Gastrointestinal stromal tumour, Receptor autoradiography, RT-PCR, Small cell lung cancer",
author = "Meike K{\"o}rner and Beatrice Waser and Reubi, {Jean Claude} and Miller, {Laurence J}",
year = "2010",
month = "4",
doi = "10.1111/j.1582-4934.2009.00859.x",
language = "English (US)",
volume = "14",
pages = "933--943",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - CCK2 receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours

AU - Körner, Meike

AU - Waser, Beatrice

AU - Reubi, Jean Claude

AU - Miller, Laurence J

PY - 2010/4

Y1 - 2010/4

N2 - The wild-type cholecystokinin type 2 (CCK2) receptor is expressed in many gastrointestinal and lung tumours. A splice variant of the CCK2 receptor with retention of intron 4 (CCK2Ri4sv) showing constitutive activity associated with increased tumour growth was described in few colorectal, pancreatic and gastric cancers. Given the potential functional and clinical importance of this spliceoform, its occurrence was quantitatively characterized in a broad collection of 81 gastrointestinal and lung tumours, including insulinomas, ileal carcinoids, gastrointestinal stromal tumours (GIST), gastric, colorectal and pancreatic ductal adenocarcinomas, cholangiocellular and hepatocellular carcinomas, small cell lung cancers (SCLC), non-SCLC (nSCLC) and bronchopulmonary carcinoids, as well as 21 samples of corresponding normal tissues. These samples were assessed for transcript expression of total CCK2 receptor, wild-type CCK2 receptor and CCK2Ri4sv with end-point and real-time RT-PCR, and for total CCK2 receptor protein expression on the basis of receptor binding with in vitro receptor autoradiography. Wild-type CCK2 receptor transcripts were found in the vast majority of tumours and normal tissues. CCK2Ri4sv mRNA expression was present predominantly in insulinomas (incidence 100%), GIST (100%) and SCLC (67%), but rarely in pancreatic, colorectal and gastric carcinomas and nSCLC. It was not found in wild-type CCK2 receptor negative tumours or any normal tissues tested. CCK2Ri4sv transcript levels in individual tumours were low, ranging from 0.02% to 0.14% of total CCK2 receptor transcripts. In conclusion, the CCK2Ri4sv is a marker of specific gastrointestinal and lung tumours. With its high selectivity for and high incidence in SCLC and GIST, it may represent an attractive clinical target.

AB - The wild-type cholecystokinin type 2 (CCK2) receptor is expressed in many gastrointestinal and lung tumours. A splice variant of the CCK2 receptor with retention of intron 4 (CCK2Ri4sv) showing constitutive activity associated with increased tumour growth was described in few colorectal, pancreatic and gastric cancers. Given the potential functional and clinical importance of this spliceoform, its occurrence was quantitatively characterized in a broad collection of 81 gastrointestinal and lung tumours, including insulinomas, ileal carcinoids, gastrointestinal stromal tumours (GIST), gastric, colorectal and pancreatic ductal adenocarcinomas, cholangiocellular and hepatocellular carcinomas, small cell lung cancers (SCLC), non-SCLC (nSCLC) and bronchopulmonary carcinoids, as well as 21 samples of corresponding normal tissues. These samples were assessed for transcript expression of total CCK2 receptor, wild-type CCK2 receptor and CCK2Ri4sv with end-point and real-time RT-PCR, and for total CCK2 receptor protein expression on the basis of receptor binding with in vitro receptor autoradiography. Wild-type CCK2 receptor transcripts were found in the vast majority of tumours and normal tissues. CCK2Ri4sv mRNA expression was present predominantly in insulinomas (incidence 100%), GIST (100%) and SCLC (67%), but rarely in pancreatic, colorectal and gastric carcinomas and nSCLC. It was not found in wild-type CCK2 receptor negative tumours or any normal tissues tested. CCK2Ri4sv transcript levels in individual tumours were low, ranging from 0.02% to 0.14% of total CCK2 receptor transcripts. In conclusion, the CCK2Ri4sv is a marker of specific gastrointestinal and lung tumours. With its high selectivity for and high incidence in SCLC and GIST, it may represent an attractive clinical target.

KW - CCK receptor intron 4 splice variant

KW - Gastrointestinal stromal tumour

KW - Receptor autoradiography

KW - RT-PCR

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=77953938452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953938452&partnerID=8YFLogxK

U2 - 10.1111/j.1582-4934.2009.00859.x

DO - 10.1111/j.1582-4934.2009.00859.x

M3 - Article

C2 - 19627395

AN - SCOPUS:77953938452

VL - 14

SP - 933

EP - 943

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 4

ER -